Significant Growth of Biotech Investor Participation Expected for Seventh Annual BIO Investor ForumOct 21 2008
WASHINGTON, D.C. (Tuesday, October 21, 2008) - The Biotechnology Industry Organization (BIO) today announces a substantial increase in anticipated investor participation in the Seventh Annual BIO... |
|
BIO Renews Endorsement of Monitor Liability Managers, Inc.Oct 17 2008
... |
|
Leading Clinical Investigators and Physicians to Address Key Issues for Clinical-Stage Biopharmaceuticals at Seventh Annual BIO Investor ForumOct 16 2008
WASHINGTON, D.C. (Thursday, October 16, 2008) - The Biotechnology Industry Organization (BIO) today announced that 28 renowned clinicians and investigators will be featured in Therapeutic Workshops... |
|
Revenue Recognition Principles Negatively Impact the Biotechnology Industry, New Study ConfirmsOct 10 2008
... |
|
Plenary and Business Panels to Address Growing Challenges of Small Biotech Companies at the BIO Investor ForumOct 9 2008
WASHINGTON, D.C. (Thursday, October 09, 2008) - The Biotechnology Industry Organization (BIO) today announces plenary sessions and roundtables planned for the Seventh Annual BIO Investor Forum that... |
|
BIO Supports Modernization of USDA Plant Biotech RegsOct 6 2008
WASHINGTON, D.C. (Monday, October 06, 2008) - As part of the process to update its regulations for plant biotechnology, USDA’s Animal and Plant Health Inspection Service (APHIS) released today a... |
|
BIO Lauds Senate Passage of Strengthened Two-Year R&D CreditOct 2 2008
WASHINGTON, D.C. (Thursday, October 02, 2008) - The Biotechnology Industry Organization (BIO) today lauded U.S. Senate passage of a 2-year extension of the federal research and development (R... |
|
Patient Safety and Incentives for Continued Innovation Must be Provided in Any Pathway for the Approval of Follow-On Biologics, BIO Tells FTCOct 1 2008
WASHINGTON, D.C. (October 1, 2008) – Patient safety and data exclusivity to preserve biomedical innovation should stand at the center of a regulatory approval pathway for follow-on biologics,... |
|
BIO Commends SEC Efforts to Combat Illegal “Naked” Short SellingSep 30 2008
... |
|
AARP Drug Price Survey Overlooks Critical Factors, Says BIOSep 26 2008
... |
